GGrantIndex
← Search

Cancer Center Support Grant

$150,000P30FY2014CANIH

Vanderbilt University, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

DESCRIPTION (provided by applicant): This is the third competing continuation application for the Cancer Center Support Grant at Vanderbilt lngram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center (VUMC) that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences, Engineering; Peabody School of Education and the fully integrated Veterans Administration Medical Center. Most facilities are located on one campus, which promotes interactions, sharing of resources, and collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific authorities and responsibilities are: 1) to conduct, coordinate and integrate cancer-related activities of Vanderbilt University; 2) to carry out, support and enhance cancer research throughout the University; 3) to develop, manage, and provide cancer education programs; and 4) to coordinate and integrate the care of cancer patients at VUMC. The research objectives are accomplished through seven research programs, two of which evolved out of previous programs and are considered new since the previous application. The programs are: Host-Tumor Interactions, Signal Transduction and Cell Proliferation, Genome Maintenance (new), Gastrointestinal Cancer, Thoracic/Head & Neck Cancer (new), Breast Cancer, and Cancer Epidemiology, Prevention and Control. Thirteen shared resources are proposed, 11 previously supported and two new. There has been remarkable VICC growth and accomplishments over the past project period. VICC has been awarded 11 new multi-investigator and six new training grants. In addition, we successfully renewed all three NCI SPOREs as well as eight multi-investigator and 11 training grants. With these and many other NCI grants, we increased our NCI funding by 62%. Significant investments have been made in cancer drug discovery, personalized cancer medicine, cancer epidemiology prevention and control, genomics, proteomics, informatics, bioinformatics, diversity initiatives, and cancer health disparities. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 66 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research, innovative clinical trials, evidence-based patient-care, prevention, education, and community activities.

View original record on NIH RePORTER →